Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...

The EU development comes shortly after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of Leqembi in the US, after a biweekly IV initial induction course ...

Future of Healthcategory· January 27, 2025 US FDA OKs monthly maintenance dosing for Eisai ... Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...